Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEFZIL vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Pharyngitis/tonsillitis (Streptococcus pyogenes),Otitis media (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis),Acute sinusitis,Acute bacterial exacerbation of chronic bronchitis,Skin and skin structure infections (uncomplicated)
Mild to moderate pain,Fever
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Cefprozil is not extensively metabolized; approximately 60% of the dose is excreted unchanged in the urine. Renal excretion via tubular secretion and glomerular filtration.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
65-80% bound to plasma proteins (mainly albumin)
Approximately 10-20% bound to serum albumin; extensive tissue binding.
0.23-0.35 L/kg; distributes well into body fluids and tissues including skin, soft tissue, and respiratory tract
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 90-95%
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl 30-49 m L/min: 250 mg twice daily; Cr Cl 10-29 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
6 months to 12 years: 30 mg/kg/day divided twice daily (max 1 g/day); for pharyngitis/tonsillitis: 20 mg/kg/day divided twice daily (max 500 mg/day).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Adjust dose based on renal function; no specific geriatric dose adjustments other than renal considerations.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Hypersensitivity reactions (including anaphylaxis) in penicillin-allergic patients,Clostridium difficile-associated diarrhea (CDAD),Seizures with high doses or renal impairment,Hemolytic anemia (rare),Prolonged prothrombin time (rare)
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to cefprozil or other cephalosporins,Immediate-type hypersensitivity to penicillins (cross-reactivity risk)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No clinically significant food interactions. High-fat meals may slightly delay absorption but do not affect overall absorption extent. Avoid alcohol during therapy as it may increase risk of disulfiram-like reaction (rare with cephalosporins).
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies. Risk cannot be ruled out. First trimester: No reported teratogenicity in animal studies; clinical data insufficient. Second/third trimester: No known risk; use only if clearly needed.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Cefprozil (CEFZIL) is excreted in human milk in low amounts. Milk-to-plasma ratio is approximately 0.3. Considered compatible with breastfeeding; however, monitor infant for potential gastrointestinal effects.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No dose adjustment routinely required. Physiologic changes in pregnancy (increased renal clearance, volume of distribution) may require higher doses for severe infections, but data insufficient to recommend specific adjustments. Use standard adult dosing unless renal impairment.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
CEFZIL (cefprozil) is a second-generation cephalosporin with activity against Gram-positive cocci (including Streptococcus pyogenes, Streptococcus pneumoniae, and methicillin-susceptible Staphylococcus aureus) and some Gram-negative bacteria (Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli). It has a longer half-life (1.3 hours) compared to cephalexin, allowing twice-daily dosing. It is FDA-approved for acute sinusitis, pharyngitis/tonsillitis, otitis media, acute bacterial exacerbation of chronic bronchitis, secondary bacterial infection of acute bronchitis, and uncomplicated skin and skin structure infections. Note that it is not reliable against penicillin-resistant S. pneumoniae or beta-lactamase-producing H. influenzae (though it is more stable than first-generation agents). In penicillin-allergic patients, cross-reactivity risk is low but not zero (avoid if immediate-type hypersensitivity to penicillin). Dose adjustment required for creatinine clearance <30 m L/min: give standard dose every 12 hours for first dose, then 50% of standard dose every 12 hours. Available as 250 mg and 500 mg tablets and as an oral suspension (125 mg/5 m L or 250 mg/5 m L). Refrigerate suspension after reconstitution; discard after 14 days.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take this medication exactly as prescribed by your doctor, usually every 12 hours.,You may take this medication with or without food; however, taking with food may help reduce stomach upset.,Complete the full course of therapy, even if you feel better, to reduce the risk of antibiotic resistance.,Shake the oral suspension well before each dose. Use a proper measuring spoon or dosing syringe to ensure accurate dose.,Store the oral suspension in the refrigerator (not freezer) and discard any unused portion after 14 days.,Notify your doctor if you develop diarrhea, especially if it is watery or bloody; do not use anti-diarrhea medications without consulting your doctor.,Seek immediate medical attention if you experience signs of an allergic reaction: rash, hives, itching, difficulty breathing, tightness in chest, swelling of face/mouth/tongue.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEFZIL vs ACEPHEN, answered by our medical review team.
CEFZIL is a Cephalosporin Antibiotic that works by Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEFZIL and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEFZIL is: 500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEFZIL and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEFZIL is classified as Category C. FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies. Risk cannot be ruled out. First trimester: No reported teratogenicity in a. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.